Envestnet Asset Management
CLRB icon

Envestnet Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Envestnet Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-348
Closed -$124K – 3679
2021
Q2 		$124K Buy
348
+271
+352% +$118K ﹤0.01% 3547
2021
Q1 		$37K Buy
77
+36
+88% +$21.4K ﹤0.01% 3463
2020
Q4 		$26K Buy
+41
New +$18.8K ﹤0.01% 3249

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Envestnet Asset Management's CLRB Position: Q3 2021 in Review

Envestnet Asset Management sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 348 shares — an estimated $124K sold.

Envestnet Asset Management first reported a position in CLRB in Q4 2020 and held it in 3 quarters. The position peaked at $124K in Q2 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • Envestnet Asset Management reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • Envestnet Asset Management sold 348 Cellectar Biosciences shares in Q3 2021, an estimated $124K.
  • Envestnet Asset Management first reported a position in Cellectar Biosciences in Q4 2020 and held it in 3 quarters.
  • Envestnet Asset Management's Cellectar Biosciences position peaked at $124K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on Envestnet Asset Management's 13F filing for Q3 2021, filed 7 Oct 2021.